Methods In this retrospective cohort study, 125 474 adults with overweight or obesity newly initiated treatment with a dual-labeled GLP-1 RA (liraglutide, semaglutide, or tirzepatide) between January 1, 2018, and December 31, 2023, with a baseline body mass index of 27 or more, an available weight measurement within 60 days before initiation, and regular care in the year before initiation were identified using electronic health record data from a collective of US health care systems
Community-reported effects (nausea, GI discomfort, headache) come only from anecdotal vendor/forum sources, not controlled studies
Start your intake Insurance Coverage Criteria: What Carriers Actually Require Most major insurers (UnitedHealth, Cigna, Aetna, Anthem) cover GLP-1 agonists for type 2 diabetes at any BMI and for weight management when BMI 30 or 27 with comorbidity
Evidence suggests that GLP-1 has neuroprotective effects in addition to having effects on appetite regulation by decreasing appetite and increasing satiety (14, 15)
This explains why the severity of endometriosis-related infertility can be predicted to some extent by measuring iron levels in ectopic cysts
And for a lot of GLP-1 users, that means something small, easy to digest, and ready in minutes